Clinical Study Data Request Registered Users, Please Login

Scroll down the list of studies provided below. Studies are listed by study medicine in alphabetical order. Alternatively you can browse the list of studies using the search function.

To select studies and submit a research proposal or enquiry, go back to the Home page and select View and submit.

This takes you back to the previous page to enable you to view studies from a different sponsor.

Select medicine, medical condition or phase from the drop down boxes. This searches all the available clinical studies. Selecting from more than one drop down box will “and” the criteria.

Find by:


Alternatively search for studies using the Lilly Clinical Study Identification Number or study title by entering text and clicking search.

 

272 found

Click the study title to find more information about the study.

LILLY-B4Z-MC-HFBD
A Randomized, Double-Blind Study of Tomoxetine Hydrochloride, Methylphenidate Hydrochloride, and Placebo in Pediatric Outpatients with Attention Deficit/Hyperactivity Disorder

Medicine: Atomoxetine, Condition: Attention Deficit Hyperactivity Disorder, Phase: 2, Clinical Study ID: B4Z-MC-HFBD, Sponsor: Lilly
LILLY-B4Z-MC-HFBF
Long-Term, Open-Label, Safety Study of Tomoxetine Hydrochloride in Patients, 6 Years and Older

Medicine: Atomoxetine, Condition: Attention Deficit Hyperactivity Disorder, Phase: 2, Clinical Study ID: B4Z-MC-HFBF, Sponsor: Lilly
LILLY-B4Z-MC-HFBK
A Randomized, Double-Blind Study of Tomoxetine Hydrochloride, Methylphenidate Hydrochloride, and Placebo in Pediatric Outpatients with Attention-Deficit/Hyperactivity Disorder

Medicine: Atomoxetine, Condition: Attention Deficit Hyperactivity Disorder, Phase: 2, Clinical Study ID: B4Z-MC-HFBK, Sponsor: Lilly
LILLY-B4Z-MC-LYAA
A Phase III Randomized, Double-Blind Comparison of Placebo and Tomoxetine Hydrochloride in Adult Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder.

Medicine: Atomoxetine, Condition: Attention Deficit Hyperactivity Disorder, Phase: 3, Clinical Study ID: B4Z-MC-LYAA, Sponsor: Lilly
LILLY-B4Z-MC-LYAB
A Phase III Open-Label Safety and Efficacy Study of Tomoxetine Hydrochloride in Outpatients with ADHD, Ages 6 to 18 Years

Medicine: Atomoxetine, Condition: Attention Deficit Hyperactivity Disorder, Phase: 3, Clinical Study ID: B4Z-MC-LYAB, Sponsor: Lilly
LILLY-B4Z-MC-LYAC
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges (mg/kg/day) of Tomoxetine with Placebo in Child and Adolescent Outpatients with ADHD, Aged 8 to 18 Years

Medicine: Atomoxetine, Condition: Attention Deficit Hyperactivity Disorder, Phase: 3, Clinical Study ID: B4Z-MC-LYAC, Sponsor: Lilly
LILLY-B4Z-MC-LYAF
Relapse Prevention After 10-Week and 52-Week Treatment with Tomoxetine Hydrochloride in Children with Attention-Deficit/Hyperactivity Disorder

Medicine: Atomoxetine, Condition: Attention Deficit Hyperactivity Disorder, Phase: 2/3, Clinical Study ID: B4Z-MC-LYAF, Sponsor: Lilly
LILLY-B4Z-MC-LYAO
A Phase III Randomized, Double-Blind Comparison of Placebo and Tomoxetine Hydrochloride in Adult Outpatients with DSM-IV Attention- Deficit/Hyperactivity Disorder.

Medicine: Atomoxetine, Condition: Attention Deficit Hyperactivity Disorder, Phase: 3, Clinical Study ID: B4Z-MC-LYAO, Sponsor: Lilly
LILLY-B4Z-MC-LYAQ
Safety and Efficacy of Atomoxetine or Atomoxetine Plus Fluoxetine in the Treatment of Mixed Attentional and Affective Disorders

Medicine: Atomoxetine, Condition: Attention Deficit Hyperactivity Disorder, Phase: 3, Clinical Study ID: B4Z-MC-LYAQ, Sponsor: Lilly
LILLY-B4Z-MC-LYAS
A Randomized, Double-Blind Study of Tomoxetine Hydrochloride and Placebo in Pediatric Outpatients with Attention Deficit/Hyperactivity Disorder and Comorbid Tic Disorders

Medicine: Atomoxetine, Condition: Attention Deficit Hyperactivity Disorder, Phase: 3, Clinical Study ID: B4Z-MC-LYAS, Sponsor: Lilly
First Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  ... Next Last